SI-BONE - SIBN Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings or view top-rated stocks.

7 brokers have issued 12 month price objectives for SI-BONE's shares. Their SIBN share price forecasts range from $20.00 to $32.00. On average, they predict the company's stock price to reach $24.63 in the next year. This suggests a possible upside of 26.7% from the stock's current price.
View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts.

SI-BONE's stock was trading at $13.60 at the beginning of the year. Since then, SIBN shares have increased by 42.9% and is now trading at $19.44.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SIBN earnings forecast.

SI-BONE, Inc. (NASDAQ:SIBN) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The company earned $22.29 million during the quarter, compared to analysts' expectations of $22.71 million. SI-BONE had a negative trailing twelve-month return on equity of 56.40% and a negative net margin of 57.57%. During the same period in the prior year, the firm posted ($0.33) earnings per share.

ETFs with the largest weight of SI-BONE (NASDAQ:SIBN) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and BlackRock Future Health ETF (BMED).iShares U.S. Medical Devices ETF (IHI) and

SI-BONE updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $124.00 million-$127.00 million, compared to the consensus revenue estimate of $125.26 million.

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include Honeywell International (HON), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

(SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

SI-BONE's stock is owned by a number of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (11.28%), First Light Asset Management LLC (6.10%), Impax Asset Management Group plc (3.48%), Granahan Investment Management LLC (3.37%), American Century Companies Inc. (3.15%) and Point72 Asset Management L.P. (2.76%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky.
View institutional ownership trends.

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIBN stock can currently be purchased for approximately $19.44.

SI-BONE (NASDAQ:SIBN) has a market capitalization of $680.21 million and generates $106.41 million in revenue each year. The company earns $-61,260,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

The company employs 352 workers across the globe.

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for the company is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com.